文献速递艾滋病与性传播感染

广泛中和HIV-1单抗VRC01在暴露新生儿中的安全性、耐受性与药代动力学

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
PubMed 文献 · J Infect Dis · 2020-01-01

本研究为1期安全性与药代动力学研究,纳入40名HIV暴露婴儿,分别接受单次皮下20或40 mg/kg VRC01,或多次给药(出生时40 mg/kg后每月20 mg/kg)。结果显示皮下VRC01安全且耐受良好,仅见轻度至中度局部反应,40 mg/kg剂量下14名婴儿中13名在第28天达到血清50 mcg/mL目标浓度,多次给药婴儿在母乳喂养期间维持该浓度以上。

要点

  • 皮下VRC01单次或多次给药在年幼婴儿中安全且耐受良好。
  • 40 mg/kg单次给药后14名婴儿中13名在第28天达到血清50 mcg/mL目标浓度。
  • 多次给药婴儿在母乳喂养期间维持血清浓度大于50 mcg/mL。

核心结论

  • 皮下VRC01单次或多次给药在年幼婴儿中安全且耐受良好,适合进一步研究用于预防婴儿HIV传播。

研究设计与样本

  • 1期安全性与药代动力学研究,共纳入40名HIV暴露婴儿(美国21名,非洲19名)。
  • 剂量1组和2组分别单次皮下注射20或40 mg/kg VRC01,剂量3组为母乳喂养婴儿出生后40 mg/kg皮下注射后每月20 mg/kg皮下注射。
  • 所有婴儿均接受适当的抗逆转录病毒预防。

主要发现

  • 皮下VRC01安全且耐受良好,仅见轻度至中度局部反应,主要为红斑,迅速消退。
  • 多次给药婴儿的局部反应随后续注射减少。
  • VRC01给药后迅速吸收,峰值浓度出现在给药后1-6天。
  • 40 mg/kg剂量组14名婴儿中13名在第28天达到血清50 mcg/mL目标浓度。
  • 剂量3组婴儿在母乳喂养期间维持浓度大于50 mcg/mL。

临床怎么用

  • 皮下VRC01可作为进一步研究用于预防婴儿HIV传播的候选方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although mother-to-child human immunodeficiency virus (HIV) transmission has dramatically decreased with maternal antiretroviral therapy, breast milk transmission accounts for most of the 180 000 new infant HIV infections annually. Broadly neutralizing antibodies (bNAb) may further reduce transmission. METHODS: A Phase 1 safety and pharmacokinetic study was conducted: a single subcutaneous (SC) dose of 20 or 40 mg/kg (Dose Groups 1 and 2, respectively) of the bNAb VRC01 was administered to HIV-exposed infants soon after birth. Breastfeeding infants (Dose Group 3) received 40 mg/kg SC VRC01 after birth and then 20 mg/kg/dose SC monthly. All infants received appropriate antiretroviral prophylaxis. RESULTS: Forty infants were enrolled (21 in the United States, 19 in Africa). Subcutaneous VRC01 was safe and well tolerated with only mild-to-moderate local reactions, primarily erythema, which rapidly resolved. For multiple-dose infants, local reactions decreased with subsequent injections. VRC01 was rapidly absorbed after administration, with peak concentrations 1-6 days postdose. The 40 mg/kg dose resulted in 13 of 14 infants achieving the serum 50 micrograms (mcg)/mL target at day 28. Dose Group 3 infants maintained concentrations greater than 50 mcg/mL throughout breastfeeding. CONCLUSIONS: Subcutaneous VRC01 as single or multiple doses is safe and well tolerated in very young infants and is suitable for further study to prevent HIV transmission in infants.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cunningham CK, McFarland EJ, Morrison RL, et al. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2020. PMID: 31681963. doi:10.1093/infdis/jiz532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。